Biopharma Vital Signs – Part 4: The New Partnership Playbook
Experts discuss how biopharma partnerships are evolving, as companies look beyond transactional supplier relationships toward more integrated, strategic, and collaborative models
False
Experts discuss how biopharma partnerships are evolving, as companies look beyond transactional supplier relationships toward more integrated, strategic, and collaborative models
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
False
False
November 2, 2026
5 min read
Early characterization and manufacturing planning can help developers choose the right formulation strategy for complex oral therapies
October 22, 2026
5 min read
Alcami’s Kerrie Powell, Senior VP of Sales, discusses the challenges of sterile biologics manufacturing and what sponsors should look for in a CDMO partner
October 22, 2026
5 min read
Rob DiCicco discusses how FDA–industry collaboration is helping sponsors rethink safety reporting, selective safety data collection, and pragmatic clinical trial design.
October 7, 2026
1 min read
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
False
Affiliations:
Specialties:
Areas of Expertise: